Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.

Published online

Journal Article

Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a novel antiviral recently approved for CMV prophylaxis following hematopoietic cell transplantation, but its efficacy in other settings is unknown. We recently used letermovir for salvage treatment in four solid organ transplant recipients with ganciclovir-resistant CMV retinitis. All patients improved clinically without known adverse drug events. However, three patients failed to maintain virologic suppression, including two patients who developed genotypically confirmed resistance to letermovir while on therapy.

Full Text

Duke Authors

Cited Authors

  • Turner, N; Strand, A; Grewal, DS; Cox, G; Arif, S; Baker, AW; Maziarz, EK; Saullo, JH; Wolfe, CR

Published Date

  • March 2019

Published In

Volume / Issue

  • 63 / 3

PubMed ID

  • 30642941

Pubmed Central ID

  • 30642941

Electronic International Standard Serial Number (EISSN)

  • 1098-6596

Digital Object Identifier (DOI)

  • 10.1128/AAC.02337-18

Language

  • eng

Conference Location

  • United States